Total Payments
$84,667
2024 Payments
$19,038
Companies
8
Transactions
152
Medicare Patients
235
Medicare Billing
$20,576
Payment Breakdown by Category
Consulting$42,211 (49.9%)
Travel$21,866 (25.8%)
Research$17,137 (20.2%)
Food & Beverage$3,440 (4.1%)
Education$13.35 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $42,211 | 11 | 49.9% |
| Travel and Lodging | $21,866 | 61 | 25.8% |
| Unspecified | $17,137 | 10 | 20.2% |
| Food and Beverage | $3,440 | 68 | 4.1% |
| Education | $13.35 | 2 | 0.0% |
Payments by Type
General
$67,530
142 transactions
Research
$17,137
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $34,073 | 30 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $26,136 | 84 | $0 (2024) |
| Merck Sharp & Dohme LLC | $11,438 | 17 | $0 (2024) |
| Zogenix Inc. | $5,000 | 1 | $0 (2020) |
| Gilead Sciences Inc | $4,458 | 14 | $0 (2017) |
| VIVUS, Inc. | $2,549 | 3 | $0 (2017) |
| Allergan Inc. | $541.67 | 1 | $0 (2017) |
| PFIZER INC. | $471.00 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,038 | 22 | United Therapeutics Corporation ($13,717) |
| 2023 | $6,117 | 9 | Merck Sharp & Dohme LLC ($6,052) |
| 2022 | $291.08 | 3 | United Therapeutics Corporation ($146.08) |
| 2021 | $8,323 | 3 | United Therapeutics Corporation ($8,323) |
| 2020 | $5,000 | 1 | Zogenix Inc. ($5,000) |
| 2019 | $12,655 | 24 | United Therapeutics Corporation ($11,845) |
| 2018 | $6,767 | 28 | Actelion Pharmaceuticals US, Inc. ($6,767) |
| 2017 | $26,476 | 62 | Actelion Pharmaceuticals US, Inc. ($18,413) |
All Payment Transactions
152 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,270.00 | General |
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $220.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $220.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $64.11 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $51.83 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $34.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $220.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/08/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Travel and Lodging | In-kind items and services | $702.48 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 10/08/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Travel and Lodging | Cash or cash equivalent | $351.96 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 10/08/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Food and Beverage | In-kind items and services | $144.00 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 10/08/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Travel and Lodging | Cash or cash equivalent | $73.58 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 08/26/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Consulting Fee | Cash or cash equivalent | $10,480.00 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 07/18/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Travel and Lodging | In-kind items and services | $792.98 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 07/18/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 07/18/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Travel and Lodging | Cash or cash equivalent | $74.46 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 07/18/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Food and Beverage | In-kind items and services | $48.00 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 07/18/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Food and Beverage | In-kind items and services | $47.00 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 07/17/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Travel and Lodging | In-kind items and services | $792.98 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 07/17/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN, TYVASO | Travel and Lodging | Cash or cash equivalent | $74.46 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 06/11/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Education | In-kind items and services | $10.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/21/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $79.50 | General |
| 10/31/2023 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: Cardiology | ||||||
| 06/01/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,880.00 | General |
| 06/01/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| UNSPECIFIED RESEARCH PROJECTS | United Therapeutics Corporation | $8,817 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 29 | 43 | $14,270 | $4,442 |
| 2022 | 2 | 35 | 62 | $15,156 | $4,704 |
| 2021 | 3 | 61 | 98 | $22,561 | $6,728 |
| 2020 | 3 | 110 | 139 | $15,637 | $4,701 |
Total Patients
235
Total Services
342
Medicare Billing
$20,576
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 30 | $7,770 | $2,772 | 35.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $6,500 | $1,670 | 25.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 51 | $13,209 | $4,086 | 30.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 11 | 11 | $1,947 | $618.43 | 31.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 29 | 63 | $16,317 | $5,119 | 31.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $5,500 | $1,467 | 26.7% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 21 | 24 | $744.00 | $142.48 | 19.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 42 | $10,878 | $3,518 | 32.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 12 | 12 | $2,124 | $652.20 | 30.7% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 81 | 85 | $2,635 | $531.18 | 20.2% |
About Stephen Chan
Stephen Chan is a Cardiovascular Disease healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1730160524.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Stephen Chan has received a total of $84,667 in payments from pharmaceutical and medical device companies, with $19,038 received in 2024. These payments were reported across 152 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($42,211).
As a Medicare-enrolled provider, Chan has provided services to 235 Medicare beneficiaries, totaling 342 services with total Medicare billing of $20,576. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Pittsburgh, PA
- Active Since 11/08/2005
- Last Updated 05/24/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1730160524
Products in Payments
- ORENITRAM (Drug) $16,817
- NONE (Drug) $8,817
- Fintepla (Drug) $5,000
- Letairis (Drug) $4,217
- QSYMIA (Drug) $2,549
- WINREVAIR (Biological) $821.15
- BOSENTAN (Drug) $211.70
- UPTRAVI (Drug) $23.77
- TYVASO (Drug) $2.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Pittsburgh
Dr. John Chenarides, Md, MD
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Dr. George Gabriel, Do, DO
Cardiovascular Disease — Payments: $801,111
Cardiovascular Disease $801,111
Andrew Pogozelski, M.d, M.D
Cardiovascular Disease — Payments: $442,274
Cardiovascular Disease $442,274
Mark Greathouse, Md, MD
Cardiovascular Disease — Payments: $382,075
Cardiovascular Disease $382,075
Ramzi Khalil, Md, MD
Cardiovascular Disease — Payments: $281,654
Cardiovascular Disease $281,654
David Lasorda, Do, DO
Cardiovascular Disease — Payments: $278,090
Cardiovascular Disease $278,090